A new technique involving detection of a specific protein in faeces could prove to be a reliable marker for colorectal cancer.
Clinical evaluations are being carried out by Dr Nicholas Coleman and colleagues from the Medical Research Council Cancer Cell Unit, Cambridge University, Cambridge, England, on identifying a specific protein – minichromosome maintenance protein 2 (MCM2) – which is present in cancerous colorectal cells but not normal cells.
Dr Coleman points out that colorectal cancer screening generally includes faecal occult blood testing and flexible sigmoidoscopy, “but better tests are needed if accuracy, safety, affordability, and compliance rates are to improve.
” Colorectal cancer claims at least 500,000 lives a year world-wide. Screening by detection of altered DNA in faces is labour-intensive, expensive, and may lack sensitivity because of clonal heterogeneity in colorectal carcinomas.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!